Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
Journal: Journal of lipid research
Published: June 13, 2026
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
Journal: Circulation
Published: April 21, 2025
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Journal: Nature metabolism
Published: October 13, 2023
Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.
Journal: JAMA
Published: August 22, 2023
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Journal: The New England journal of medicine
Published: November 13, 2020
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
Journal: European journal of heart failure
Published: October 12, 2020
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
Journal: Journal of the American Heart Association
Published: August 18, 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Journal: JAMA cardiology
Published: May 21, 2020
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.
Journal: JAMA cardiology
Published: April 30, 2020
Last Updated: 09/26/2026